CureVac
Revolutionizing mRNA for Life

Investor Presentation, February 2024

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CureVac at a Glance

Pioneers in Medical mRNA Applications

Founded in 2000

Headquartered in Tübingen

>1,100 employees

Manufacturing Expertise

3 GMP certified suites

1 large-scale suite in the build-up

The RNA Printer®

flexible and mobile

Prophylactic Vaccines | **Oncology** | **Molecular Therapy**



Deep clinical pipeline

Financing Business Transformation

€464.1 m
cash position*

CVAC
Nasdaq Listed

Nasdaq Biotech Index

Strategic partnerships

GSK

myNEO Therapeutics

CRISPR THERAPEUTICS

Genmab

- Operational expertise
- Development support
- Commercial execution power

*As of September 30, 2023

Corporate Growth and Transformation



2023 Selected Highlights

Oncology

Start of **Glioblastoma Phase I** study

Preclinical progress in **LNP** research

Advancing strategic collaboration with **myNEO Therapeutics**

Selection of **off-the-shelf vaccine** targets

Prophylactic Vaccines

Positive Phase 1 COVID and flu data (modified mRNA)

Start Phase 2 study in COVID-19

Start Phase 2 of combined Phase 1/2 study in flu

Manufacturing

Regulatory approvals for **The RNA Printer®**

Drug substance **manufacturing** license

Drug substance **framework** license

Corporate Progress

New leadership with deep pharma expertise

$250MM gross proceeds from public offering

Progress in defending Intellectual Property

2024 Key Catalysts

	H1 2024	H2 2024
Prophylactic Vaccines	**Phase 2 COVID-19:** Data readout ✓ **Phase 2 Seasonal flu:** Data readout	**Seasonal flu/COVID-19 combination:** Initiate clinical development
Oncology		**Phase 1 Glioblastoma:** Data readout
Molecular Therapy	**Ocular Diseases:** Preclinical data	
Manufacturing	**GMP IV:** Commercial-scale plant operational **The RNA Printer®:** Manufacturing license including formulation (drug product)	**Pandemic Preparedness Agreement** with German Government: Initiation
Corporate Development	**IP Germany:** European Patent Office Expected ruling on validity EP 3 708 **668** B1	**IP Germany:** Regional Court Düsseldorf Ruling on infringement, Sept. 10, 2024 EP 4 023 **755** B1 DE 20 2021 004 **123** U1 DE 20 2021 004 **130** U1 **IP U.S.:** Eastern district of Virginia Jury trial, start Oct 1, 2024 Validity, infringement, and potential damages All 10 patents at issue

Phase 3 COVID-19 and flu ongoing discussions with regulators

CureVac Pipeline: A Diversified Portfolio

AREA	PROGRAM		CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
PROPHYLACTIC VACCINES	2nd-Generation	COVID-19 (GSK)	**CV0601 / CV0701 (modified mRNA)**	■	■	■	
		Influenza (GSK)	**Multivalent construct (modified mRNA)**	■	■	■	
	2nd-Generation	Other (GSK)	Four undisclosed targets	■			
	1st-Generation	Rabies	CV7202	■			
	Diverse Projects	(Bill & Melinda Gates foundation)	Rota, malaria, universal influenza	■			
ONCOLOGY	Surgically Resected Glioblastoma		**CVGBM (unmodified mRNA)**	■	■		
	Solid Tumors[1)]		CV8102	■	■		
	Off-the-Shelf Cancer Vaccines	(myNEO Therapeutics)	Antigen discovery engine based on new technologies acquired with Frame Cancer Therapeutics	■			
	Personalized Cancer Vaccines			■			
MOLECULAR THERAPY	Cas9 Gene-Editing	(CRISPR Therapeutics)	CRISPR Therapeutics collaboration	■	■		NEW
	Liver Diseases		REBIRTH-Research Center collaboration	■			
	Ocular Diseases		Schepens Eye Research Institute collaboration	■			
	Therapeutic Antibodies	(Genmab)	Genmab collaboration	■			

1) Cutaneous melanoma, adenoid cystic carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck

CureVac Technology

Optimizing mRNA for Broad Range of Vaccine Applications



- Optimizing untranslated regions based on **potent, tissue-specific** regulatory elements
- Optimizations allow for increased **translation efficiency** and **immunogenicity**
- Maximizing ribosome interaction for increased protein expression enables **low dose activity**

Unique Mechanism of Action for Infectious Diseases and Oncology

MECHANISM OF ACTION

- Inducing strong antibody titers
- Inducing B and T cell responses
- Activating innate immune system
- Inducing boostable memory responses



PROPHYLACTIC VACCINES

- Active at **low dose** in humans
- Enables **multivalent** vaccines
- Fast, **large-scale** GMP production

CANCER VACCINES & IMMUNO-MODULATION

- **Innate** and **adaptive** immune activation
- Key activation of **T cell responses**
- Demonstrated **breaking of tolerance**

Second-Generation Vaccine Program in Collaboration with GlaxoSmithKline

Broad Infectious Disease Partnership with GSK

BROAD INFECTIOUS DISEASES COLLABORATION

JULY 2020

- **Five** defined infectious disease targets
- First disclosed indication: **INFLUENZA**
- Modified candidate in Phase 2 testing

FINANCIALS

- **Milestone** and **royalty** payments

COVID-19 COLLABORATION

FEBRUARY 2021

- Broadened technology: **modified mRNA**
- Advanced formats: **mono-** and **multivalent**
- Modified candidates in Phase 2 testing

FINANCIALS

- **50:50** split **costs** and **profit**

Advancing Clinical Infectious Disease Development Programs With GSK

Phase 2 Study COVID-19

- **CV0601**, monovalent candidate encoding the spike protein of BA.4-5
- **CV0701**, bivalent candidate encoding the spike protein of BA.4-5 and the original SARS-CoV-2 virus
- Licensed bivalent mRNA **comparator vaccine**
- Study **fully enrolled** at 427 participants
- Study conducted in **Australia**

Phase 2 Part Seasonal Flu

- Candidate selected from **comprehensive Phase 1 part** of combined study
- Licensed age-appropriate **comparator vaccines**
- Candidate encodes antigens matched to all **WHO-recommended flu strains**
- Study fully enrolled at **960** participants
- Study conducted in the **U.S.**, **Belgium**, **Canada** and **South Africa**
- Data expected in **2024**

Advancing Clinical Infectious Disease Development Programs With GSK

Phase 2 Study COVID-19

427 participants
aged 18 and older

Bivalent candidate
Omicron BA.4-5
and wild type

- **CV0701** high dose ✓
- **CV0701** medium dose ✓
- **CV0701** low dose ✓
- **Licensed bivalent mRNA comparator** ✓

Monovalent candidate
Omicron BA.4-5

- **CV0601** medium dose ✓

Phase 2 Part Seasonal Flu

Exp. 480 younger adults aged 18-64	Exp 480 older adults aged 65-85
Candidate dose 1	**Candidate** dose 1
Candidate dose 2	**Candidate** dose 2
Candidate dose 3	**Candidate** dose 3
Licensed comparator younger adults	**Licensed comparator older adults**

NEW COVID-19 Phase 2 Data: CV0601, Monovalent Candidate Encoding Omicron BA.4-5

CV0601: Reactogenicity profile



CV0601: Adjusted[1)] geometric mean ratios of neutralizing antibodies titers

Day 29 post- to pre-boost titers



CV0601 exhibits favorable tolerability profile and induces robust antibody boosts

1) GMR and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
2) Licensed bivalent, mRNA-based comparator vaccine

GMR: Geometric mean ratio from day 1

NEW

COVID-19 Phase 2 Data: CV0601, Monovalent Candidate Encoding Omicron BA.4-5

CV0601: Adjusted[1)] geometric mean titers of neutralizing antibodies

Day 29 post vaccination



CV0601 elicits robust antibody responses against BA.4-5 as well as the original virus

1) GMT and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
2) All GMT measured via pseudo-typed neutralization assay
3) Licensed bivalent, mRNA-based comparator vaccine

GMT: Geometric mean titer

NEW

COVID-19 Phase 2 Data: CV0701, Bivalent Candidate Encoding Omicron BA.4-5 and the Original SARS-CoV-2 Virus

CV0701: Reactogenicity profile



CV0701: Adjusted1) geometric mean ratios of neutralizing antibodies titers

Day 29 post- to pre-boost titers



CV0701 is generally well tolerated and shows meaningful immune responses at lower doses

GMR: Geometric mean ratio from day 1

1) GMR and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
2) Licensed bivalent, mRNA-based comparator vaccine

NEW

COVID-19 Phase 2 Data: CV0701, Bivalent Candidate Encoding Omicron BA.4-5 and the Original SARS-CoV-2 Virus

CV0701: Adjusted[1)] geometric mean titers of neutralizing antibodies

Day 29 post vaccination



CV0701 antibody titers match or numerically exceed comparator titers starting at medium dose level

1) GMT and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
2) All GMT measured via pseudo-typed neutralization assay
3) Licensed bivalent, mRNA-based comparator vaccine

GMT: Geometric mean titer

Influenza Phase 1 Data: Reactogenicity Across Tested Doses and Age Groups

Flu-SV-mRNA: monovalent flu construct applying modified mRNA



Modified mRNA offers broad dose range and a tolerable reactogenicity profile

1) Preliminary data prior to database lock

Influenza Phase 1 Data: Flu-SV-mRNA Boosting Activity

Ratio post- to pre-boost titers:

Ratio of serum **HI** geometric mean titers in **younger adults** (18-45 years)[1)]



Ratio of serum **HI** geometric mean titers in **older adults** (60-80 years)[1)]



Antibody increase of Flu-SV-mRNA in line with comparator vaccine already at lowest dose level

1) Preliminary data prior to database lock
2) Randomization ratio of 2:1 deviated from the ratio of 1:1 as per protocol

HI: Hemagglutinin inhibition

QIV: Quadrivalent influenza vaccine (licensed flu comparator vaccine), 2021-22 northern hemisphere strain composition

Influenza Phase 1 Data: Flu-SV-mRNA Seroconversion Rates

Flu-SV-mRNA: **Seroconversion**[1] rates

Younger adults (18-45 years)[2]



Older adults (60-80 years)[2]



Flu-SV-mRNA QIV (licensed comparator vaccine)

Flu-SV-mRNA in line with licensed comparator vaccine beginning at lowest dose

2) Preliminary data prior to database lock

1) Seroconversion: percentage of participants with:
a) pre-dose HI titer <1:10 and post-dose titer ≥1:40 or
b) pre-dose titer ≥1:10 and post-dose titer at least 4x pre-dose titer

QIV: Quadrivalent influenza vaccine (licensed flu comparator vaccine), 2021-22 northern hemisphere strain composition

Oncology

Leveraging Data on the Full Inventory of Genomic Changes



Whole Genome Sequencing of the tumor

Short- and long-read RNA sequencing

Prediction of expressed **frame** sequences

Potentially immunogenic **frame** neo-antigens

Conventional antigen discovery is restricted to mutations in the **tumor exome**

CureVac leverages the **full tumor genome** and tumor-specific **expression analysis**

Powerful bioinformatics use the full genetic inventory to identify potentially immunogenic neo-antigens as novel **cancer vaccine candidates**

Mapping the Totality of Genomic Changes for Targeted Cancer Vaccination





● point mutations and indels

Framome*

Foreign proteins as potential **vaccine targets**

*Lung cancer patient sample

Exome sequencing offers only **limited insights** into genetic changes of the tumor

Whole genome sequencing provides **full inventory** of structural variations and other tumor antigens (such as TAAs, retroviral HERVs etc.)

WGS: Whole genome sequencing TAA: Tumor associated antigens

CureVac Platform Strengths will Align to Oncology Opportunities

Off-the-Shelf Cancer Vaccines

Scalable solutions for indications with **high prevalence of shared antigens**

Personalized Cancer Vaccines

Individualized vaccines for a broad range of **solid & hematologic** malignancies

Meeting Different Patient Needs in Oncology

Off-the-Shelf Cancer Vaccines

mRNA vaccine candidates encoding multiple antigens **shared across different cancer indication**



Personalized Cancer Vaccines

Custom-made mRNA vaccine candidates encoding multiple **patient-specific antigens**

Manufacturing	PRE-PRODUCED	PERSONALIZED
Patient	OFF-THE-SHELF	PERSONALIZED

Phase 1 Study in Glioblastoma Leverages Clinically Validated Shared Antigens

CVGBM: Multi-Epitope mRNA Construct



Class I glioblastoma epitopes

Class II glioblastoma epitopes

Class I reporter epitope

Linker

Phase 1 Clinical Study

Part A
Exp. 15-24 patients

CVGBM **100 µg**

CVGBM **50 µg** ✓

CVGBM **25 µg** ✓

CVGBM **12 µg** ✓

Part B
Exp. ca. 20 patients

Dose expansion

At recommended dose

UTR: Untranslated region SP: Signal peptide TM/cyto: Transmembrane and cytosolic domain

Preclinical Validation of CureVac's Multiepitope Cancer Vaccine Design in Mice

Ten B16.F10 murine melanoma-derived epitopes



B16.F10 mouse tumor model:

- Check-point inhibitor resistant model
- Immune-suppressing microenvironment
- Poorly immunogenic tumors

Immunogenicity in mice across full multiepitope construct[2)]

Day 21: strong CD8+ T cell responses against **five** encoded epitopes



Day 21: strong CD4+ T cell response against **two** encoded epitopes



Efficacy in tumor bearing mice[2)]

Significantly extended survival from a median of **23.2 days** to **30.9 days**



B16 mRNA construct Control mRNA Untreated

IFN: Interferon TNF: Tumor necrosis factor 1) Wildtype derived 2) Method: 3 weekly vaccinations, 5 µg intramuscular

Molecular Therapy

LNP: Tailoring Biological Activity for Improved Prophylactic and Cancer Vaccines

Prophylactic Vaccines

- Strong **humoral responses**, induction of **antibodies**
- High **tolerability**, minimized side effects and reactogenicity
- High **stability** for easy large-scale delivery and **long-term storage**

Cancer Vaccines

- Strong **cellular responses**, induction of **tumor-killing T cells**
- Strong systemic activation of **signaling pathways** to maximize immune response
- Maximized **mRNA uptake** into immune cells for highest **efficacy**

Tailoring Biological Activity for Improved Prophylactic and Cancer Vaccines

Testing LNPs with varying components and concentrations
In vitro stimulation of immune signaling activity in human PBMCs

Cytokine:
IFN-α2



Inflammation marker:
IL-6



CD80 marker:
monocyte activation



CD80 marker:
pDC activation



Strong induction of
cytokines

T cell relevant immune
signaling pathways

Strong induction of
innate immune cells

PBMC: peripheral blood mononuclear cells

pDC: plasmacytoid dendritic cells

Proprietary Non-PEG LNP: Highly Localized and Immune-Active mRNA Delivery

Biodistribution
Localization of antigen expression in mice*



Systemic interferon alpha / cellular activity
Induction of interferon alpha / interferon gamma in mice*



Humoral activity
Induction of neutralizing antibody titers against rabies in mice*



*Intramuscular injection, 8µg dose

Intellectual Property Portfolio

One of the Largest and Most Diverse mRNA Patent Portfolios with >1,000 issued Patents



NSCLC: Non-small cell lung cancer RSV: Respiratory syncytial virus PCA: Prostate cancer

Independent Analysis of Strongest Patents in mRNA Vaccines Technology[1)]



1) Source: PatentSight – a LexisNexis company, Technology Field Benchmark, Retrieval Date May 4, **2022**.

Broad Protection of CureVac Innovation in Germany

Intellectual Property Rights - By Type

Patents at issue	**Grant date**	**Expiry date**
1. EP 1 857 **122** B1	Dec 1, 2010	Jun 5, 2022
2. EP 3 708 **668** B1	Jul 27, 2022	Dec 11, 2035
3. EP 4 023 **755** B1	Apr 26, 2023	Dec 11, 2035

Utility Models at issue	**Grant date**	**Expiry date**
4. DE 20 2015 009 **961** U1	Jan 25, 2021	Dec 11, 2025
5. DE 20 2015 009 **974** U1	Feb 17, 2022	Dec 11, 2025
6. DE 20 2021 003 **575** U1	Jan 17, 2022	Feb 3, 2031
7. DE 20 2021 004 **123** U1	Oct 26, 2022	Feb 3, 2031
8. DE 20 2021 004 **130** U1	Oct 26, 2022	Feb 3, 2031

Intellectual Property Rights - By Patent Family

1. G/C Enrichment (*Foundational mRNA technology*)	EP 1 857 **122** B1
2. Split Poly-A Tail (*Foundational mRNA technology*)	EP 3 708 **668** B1 EP 4 023 **755** B1 DE 20 2015 009 **961** U1 DE 20 2015 009 **974** U1
3. Coronavirus vaccine (*SARS-CoV-2 vaccine design*)	DE 20 2021 003 **575** U1 DE 20 2021 004 **123** U1 DE 20 2021 004 **130** U1

Bifurcated German Process to Assess Infringement and Validity Per IP Right



Defending CureVac's Intellectual Property in Germany

Infringement

Regional Court Düsseldorf
First ruling, Sep 28
Ruling suspended
EP 3 708 **668** B1
DE 20 2015 009 **961** U1
DE 20 2015 009 **974** U1
DE 20 2021 003 **575** U1

Regional Court Düsseldorf
Hearing, Aug 15
EP 3 708 **668** B1
EP 1 857 **122** B1
DE 20 2015 009 **961** U1
DE 20 2015 009 **974** U1
DE 20 2021 003 **575** U1

Regional Court Düsseldorf
IP right addition, Jul 12
EP 4 023 **755** B1
DE 20 2021 004 **123** U1
DE 20 2021 004 **130** U1

Regional Court Düsseldorf
First ruling, Dec 28
Ruling suspended
EP 1 857 **122** B1

Regional Court Düsseldorf
Hearing, Sep 10
EP 4 023 **755** B1
DE 20 2021 004 **123** U1
DE 20 2021 004 **130** U1

2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

European Patent Office
Exp. First ruling
EP 3 708 **668** B1

Expt. appeal before German Federal Court of Justice

Validity

German Federal Patent Court
Positive prelim. opinion, Apr 6
EP 1 857 **122** B1

German Federal Patent Court
First ruling, Dec 19
German part of patent revoked
Ruling to be appealed
EP 1 857 **122** B1

Broad Protection of CureVac Innovation in the U.S.

Intellectual Property Rights

Patents at issue	**Grant date**	**Expiry date**
1. US 11 135 **312** B2	Oct 5, 2021	Feb 10, 2026
2. US 11 149 **278** B2	Oct 19, 2021	Feb 2, 2036
3. US 11 286 **492** B2	Mar 29, 2022	Dec 11, 2035
4. US 11 345 **920** B2	May 31, 2022	Dec 11, 2035
5. US 11 241 **493** B2	Sep 1, 2020	Jul 10, 2036
6. US 11 471 **525** B2	Feb 8, 2022	Feb 3, 2041
7. US 11 576 **966** B2	Oct 18, 2022	Feb 3, 2041
8. US 11 596 **686** B2	Feb 14, 2023	Feb 3, 2041
9. US 10 760 **070** B2	Mar 7, 2023	Feb 3, 2041
10. US 11 667 **910** B2	Jun 6, 2023	May 30, 2036

Intellectual Property Rights - By Invention

1. G/C Enrichment (*Foundational mRNA technology*)	US 11 135 **312** B2
2. Split Poly-A Tail (*Foundational mRNA technology*)	US 11 149 **278** B2 US 11 286 **492** B2 US 11 345 **920** B2
3. Coronavirus Vaccine (*SARS-CoV-2 vaccine design*)	US 11 241 **493** B2 US 11 471 **525** B2 US 11 576 **966** B2 US 11 596 **686** B2
4. Filtration (*Purification manufacture*)	US 10 760 **070** B2 US 11 667 **910** B2

Defending CureVac's Intellectual Property in the U.S.

Original patents
Declarative Judgment Action by PFE/BNTX on Jul 25, 2022

US 11 135 **312** B2
US 11 149 **278** B2
US 11 241 **493** B2

Eastern District of Virginia
CVAC counter claim, May 19

Patent addition

US 11 286 **492** B2
US 11 345 **920** B2
US 10 760 **070** B2
US 11 471 **525** B2
US 11 576 **966** B2
US 11 596 **686** B2

Patent addition, Jul 12
US 11 667 **910** B2

Court Transfer
From **Federal District Court of Massachusetts**
to **Eastern District of Virginia, May 16**

All intellectual property rights will be decided in one jury trial

Eastern District of Virginia
Jury trial start, Oct 1

Trial on all ten patents for:

- **Validity**
- **Infringement**
- **Potential damages**

Potential appeal



Manufacturing

Highly Flexible Manufacturing Landscape Serving Different Lifecycle Needs

	Research, Technology & Development	**Technical Development**	**Inhouse plants GMP I to III**	**Inhouse plant GMP IV** *In the build up*	**The RNA Printer®** *In regulatory approval*
FLEXIBILITY	mRNA design	Preclinical studies	Clinical studies / early commercial production	Commercial production	Personalized therapy
SCALABILTY	**Digital** sequence	**mg-scale /** annual output	**g to kg-scale /** annual output	**multi kg-scale /** annual output	**Individual** dosing
SPEED	+++	+++	+	++	++++

The RNA Printer® Progressing in Regulatory Review With Two Milestones

The RNA Printer®

- Highly automated end-to-end system
- Manufacturing of GMP-grade mRNA vaccines and therapeutics
- Closes small-scale manufacturing gap in oncology

Regulatory milestones achieved:

- Manufacturing license for mRNA construct
- NEW Framework license for mRNA constructs



Key Messages

Summary and Highlights

CureVac is advancing its **end-to-end** capabilities from **technology research** to **product development** to scalable **GMP-manufacturing**

Broad and diverse IP portfolio protects strong **competitive positioning as a central RNA player**

Delivering across strategic priorities with clinical lead programs in **COVID-19** and **flu** in **Phase 2** and successfully advancing **Phase 1** study in **glioblastoma**

Going into 2024 expecting **ongoing execution** driven by **key data** from three clinical programs and clinical **Phase 3 developments** in infectious diseases

Strong Q3 cash position of €464.1 million for cash reach until mid-2025 to support execution on programs; accompanied by disciplined focus on **cost management**

Financials

Solid Financing Position to Support Corporate Development

Cash position
€464.1m*

$250 million
Gross proceeds
from public offering closed
February 2023

Includes new investors
with strong
healthcare focus

Extension of **cash reach**
to **mid-2025**

ATM Facility
in place since **Sep 2021**

Subject to market conditions,
option to offer shares worth up to
$600 million

Fund our technology advancement
across all three therapeutic areas

Accelerate our Momentum
of business transformation from biotech to biopharma

*As of September 30, 2023

Q3 and First Nine Months of 2023 Cash and Condensed Consolidated P&L Data

(in € millions)	December 31, 2022	September 30, 2023
Cash and Cash Equivalents	**495.8**	**464.1**

	Three months ended September 30,		Nine month ended September 30,	
(in € millions)	2022	2023	2022	2023
Revenue	11.2	16.5	55.7	31.2
Cost of Sales, Operating Expenses & Other Operating Income	-63.6	-70.5	-183.6	-217.4
Operating Result	**-52.4**	**-54.0**	**-127.9**	**-186.2**
Financial Result	4.7	5.3	7.5	12.7
Pre-Tax Loss	**-47.7**	**-48.7**	**-120.4**	**-173.5**

Q4 and Full-Year 2022 Cash and Condensed Consolidated P&L Data

(in € millions)	December 31, 2022	December 31, 2021
Cash and Cash Equivalents	**495.8**	**811.5**

	Three months ended December 31,		Twelve months ended December 31,	
(in € millions)	2022	2021	2022	2021
Revenue	11.7	41.2	67.4	103.0
Cost of Sales, Operating Expenses & Other Operating Income	-133.2	-46.7	-316.9	-515.3
Operating Result	-121.5	**-5.5**	-249.5	**-412.3**
Financial Result	-7.2	1.0	0.3	-0.2
Pre-Tax Loss	-128.7	**-4.5**	-249.2	**-412.5**

Executing on Corporate Growth With an Experienced Team

Alexander Zehnder
PhD, MBA

Chief Executive Officer

Pierre Kemula
B.Sc.

Chief Financial Officer

Myriam Mendila
PhD

Chief Development Officer

Malte Greune
PhD

Chief Operating Officer

CureVac Investor Relations Contact

Dr. Sarah Fakih

Vice President Corporate Communications
& Investor Relations

Friedrich-Miescher-Str. 15
72076 Tübingen
Germany

Phone: +49 (0)7071 9883 -1298
Mobile: +49 (0)160 90496949
Email: sarah.fakih@curevac.com
investors@curevac.com

CVAC | NasdaqListed

CUSIP	N2451R105
ISIN	NL0015436031
WKN	A2P71U

https://www.linkedin.com/company/curevac/
@CureVac

https://twitter.com/CureVacRNA
@CureVacRNA

https://de-de.facebook.com/CureVac/
@CureVac

www.curevac.com

Thank you for your attention

CureVac
www.curevac.com